Xanthobine is a natural product with a complex structure that has attracted attention due to its potential biological activities. It is a potent inhibitor of the enzyme farnesyltransferase, which is involved in the synthesis of proteins that play a role in cancer cell growth. Research has focused on xanthobine's potential as an anticancer agent, specifically for treating leukemia. Its unique structure and biological activity make it a promising candidate for further investigation and potential drug development. The compound's biosynthesis is still under investigation, with studies exploring the role of specific enzymes and pathways in its production. Xanthobine is typically isolated from natural sources, like certain fungi and marine organisms. '
| ID Source | ID |
|---|---|
| PubMed CID | 64127 |
| CHEMBL ID | 91786 |
| SCHEMBL ID | 2501268 |
| MeSH ID | M0068834 |
| Synonym |
|---|
| CHEMBL91786 , |
| 8-bromo-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione |
| bdbm50045354 |
| 8-bromo-1,3,7-trimethyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione |
| 1h-purine-2, 8-bromo-3,7-dihydro-1,3,7-trimethyl- |
| 10381-82-5 |
| nsc11255 |
| wln: t56 bn dn fnvnvj b1 ce f1 h1 |
| nsc-11255 |
| caffeine, 8-bromo- |
| smr000038779 |
| MLS000080740 |
| 8-bromo-1,3,7-trimethyl-3,7-dihydro-1h-purine-2,6-dione |
| STK394301 |
| 8-bromo-1,3,7-trimethylpurine-2,6-dione |
| AKOS003589989 |
| HMS2285D16 |
| xanthobin |
| 8-caffeine bromide |
| nsc 11255 |
| 1h-purine-2,6-dione, 8-bromo-3,7-dihydro-1,3,7-trimethyl- |
| 8-bromocaffeine |
| 8-bromo-1,3,7-trimethyl-1h-purine-2,6(3h,7h)-dione |
| AB00401554-09 |
| 1h-purine-2,6(3h,7h)-dione, 8-bromo-1,3,7-trimethyl- |
| 8-bromo-1,3,7-trimethyl-3,7-dihydro-1h-purine-2,6-dione # |
| 8-bromo-1,3,7-trimethyl-xanthine |
| 8-bromo-1,3,7-trimethyl xanthine |
| SCHEMBL2501268 |
| DTXSID10146069 |
| 8-bromocaffeine, 98% |
| SR-01000403856-1 |
| sr-01000403856 |
| 8-bromo-1,3,7-trimethylxanthine |
| NCGC00071821-02 |
| CS-0367531 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 49.0000 | 0.0001 | 1.2092 | 9.9700 | AID31887 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ki | 12.0000 | 0.0002 | 1.4940 | 10.0000 | AID32862 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled adenosine receptor activity | Adenosine receptor A2a | Rattus norvegicus (Norway rat) |
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| Golgi membrane | Adenosine receptor A2a | Rattus norvegicus (Norway rat) |
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID31887 | Binding affinity for adenosine A1 receptor from rat brain membranes using [3H]PIA as radioligand | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. |
| AID32862 | Binding affinity for adenosine A2A receptor from rat brain membranes using [3H]CGS-21680 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||